AGGRESSIVE NON-HODGKIN LYMPHOMA
Clinical trials for AGGRESSIVE NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new AGGRESSIVE NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control Recruiting nowThis study tests whether adding two antibody drugs (mosunetuzumab and polatuzumab) after standard CAR-T cell therapy can improve tumor shrinkage in people with aggressive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. About 22 adults will receive the…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Smart scales could help keep blood cancer patients safe at home
Knowledge-focused Recruiting nowThis study looks at whether a connected scale can help monitor blood cancer patients (with lymphoma or myeloma) during chemotherapy. Thirty patients will weigh themselves daily for about 7 weeks, and their data will be sent to their medical team. The goal is to see if this approa…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:01 UTC